Is Agios Pharmaceuticals, Inc. overvalued or undervalued?

As of 20 May 2025, Agios Pharmaceuticals, Inc. has moved from an attractive to a very attractive valuation grade. The company is currently considered undervalued, particularly when compared to its peers. Key ratios include a P/E ratio of 4, a PEG ratio of 0.01, and a negative EV to EBITDA of -3.81, indicating significant potential for growth despite current challenges.
In comparison to peers, Agios Pharmaceuticals has a lower P/E ratio than PTC Therapeutics, Inc. at 5.42 and a notably lower EV to EBITDA ratio than Springworks Therapeutics, Inc., which stands at -12.44. While Agios has faced a decline in stock performance over the past year, its recent returns over the last month show an increase of 11.88%, outperforming the S&P 500's 3.83% return in the same period, reinforcing its undervalued status in the market.